SHARE

Transenterix Inc (NYSEAMERICAN:TRXC) a medical device firm that is pioneering the application of robotics to enhance minimally invasive surgery, reported that it has obtained FDA 510(k) approval for the Senhance™ Surgical Robotic System. The nod for the Senhance System in the United States is a milestone in the development of robotics and is expected to offer improvement in the value, choices and efficacy provided to surgeons, hospitals and patients.

Todd M. Pope, the CEO and President, expressed that several surgical procedures in the U.S. are performed annually laparoscopically with basic manual tools that confines surgeons’ capability, control and comfort. New choices are required that enhance the senses, comfort and control of the surgeon, lower the invasiveness of surgery for the subject, and increase value for the hospital. This new choice is none other than Senhance.

The highlights

A prevailing trend in the healthcare industry is growth and expansion of numerous healthcare domains and increasing demand for unique healthcare offerings for the aging population. Healthcare facilities appear to be focusing on a shift to turn patient-centric service providers. There are numerous notable changes in the market of late such as the launch of new telemedicine solutions, new clinical studies and trials, the development of new techniques and treatment therapies, improvements in the availability of skilled professionals and infrastructure.

Active firms in the healthcare sector with market performance and recent advancements comprise Medical Innovation Holdings, Inc. (OTCMKTS:MIHI), Transenterix, Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) and Acadia Healthcare Company Inc (NASDAQ:ACHC).

Spectrum Pharmaceuticals closed up over 4% on Friday at $19.37 with more than 3.8 million shares traded. The firm recently reported the oral presentation of interim report from a Phase 2 clinical trial assessing poziotinib in EGFR Exon 20 Mutant NSCLC by scientists’ team from the MD Anderson Cancer Center.

LEAVE A REPLY